Logo for Wave Life Sciences Ltd

Wave Life Sciences Ltd Investor Relations Material

Latest events

Logo for Wave Life Sciences Ltd

Q1 2024

Wave Life Sciences Ltd
Logo for Wave Life Sciences Ltd

Q1 2024

9 May, 2024
Logo for Wave Life Sciences Ltd

Q4 2023

6 Mar, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Wave Life Sciences Ltd

Access all reports
Wave Life Sciences Ltd. (WVE) is a biotechnology company leveraging its proprietary RNA medicines platform, PRISM, to develop transformative treatments for a range of genetic diseases. This platform enables the design, optimization, and production of novel stereopure oligonucleotides, aimed at correcting disease-causing mutations, modulating protein activity, and restoring functional protein production or reducing disease-promoting RNAs or proteins. Wave's diverse pipeline includes clinical programs targeting Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency, Huntington's disease, and a preclinical program for obesity, among others. Their approach includes multiple RNA-targeting modalities such as editing, splicing, RNA interference, and antisense silencing, showcasing their broad capabilities in addressing complex disease biology. The company is headquartered in Singapore, and its shares are listed on the Nasdaq.